Lexeo Therapeutics raised $100m to fund its gene research projects focused on cardiovascular and neurological diseases after reducing the price of its IPO. The New York-based firm’s focus ranges from rare diseases to common conditions with a genetically defined subset. Lexeo’s most advanced projects involve Friedreich’s ataxia, a rare neuromuscular disorder, and Alzheimer’s disease. The funding will also support two clinical-stage programs and others in its development pipeline.
Concerns over the security of electronic personal health information intensifies
Ascension Health warned that the personal data of its patients and staff were compromised during a ransomware attack in May that impacted around 5.6 million
